REGN — REGENERON PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 872589 ·
Last close
$957.76
Market Cap
$97.34B
52W High
$991.73
52W Low
$590.83
ADV30
899,500
Next earnings
2027-01-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 5,115,800,000 4,542,200,000 2,069,700,000 1,948,700,000 44,405,200,000 3,659,100,000 10,906,700,000
Jun 2026 4,290,700,000 3,714,200,000 1,420,500,000 1,296,900,000 41,730,600,000 2,455,800,000 10,019,200,000
Mar 2026 3,605,400,000 2,936,000,000 744,800,000 727,200,000 40,868,800,000 2,962,600,000 9,445,200,000
Dec 2025 3,884,300,000 3,299,700,000 898,600,000 844,600,000 40,558,700,000 3,118,100,000 9,301,800,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$4,681,300,000
Investing CF
$-704,200,000
Financing CF
$-3,524,800,000
CapEx
$-1,106,100,000
Dividends Paid
$-378,500,000
Buybacks
$-3,902,400,000
EPS Diluted TTM
$40.46
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$37,621,400,000
Inventory
$3,084,300,000
Receivables
$6,565,400,000
ST Investments
$5,538,800,000
EBIT TTM
$5,221,400,000
Pretax Income TTM
$5,166,000,000
Interest Exp TTM
$55,400,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$16,896,199,680
EBITDA
$5,649,699,840
Free Cash Flow
$3,065,299,968
Enterprise Value
$78,214,914,048
Total Cash
$18,858,500,096
Total Debt
$2,707,000,064
Shares Out
101,630,713
Trailing EPS
$45.24
Book Value
$329.39
ROE
14.9%
ROA
7.6%
Div Yield
0.41%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 14,342,900,000 3,702,000,000 4,504,900,000 40,558,700,000 9,301,800,000 31,256,900,000 4,978,900,000
Dec 2024 14,202,000,000 3,990,700,000 4,412,600,000 37,759,400,000 8,405,800,000 29,353,600,000 4,420,500,000
Dec 2023 13,117,200,000 4,047,100,000 3,953,600,000 33,080,200,000 7,107,100,000 25,973,100,000 4,594,000,000
Dec 2022 12,172,900,000 4,738,900,000 4,338,400,000 29,214,500,000 6,550,500,000 22,664,000,000 5,014,900,000

TTM Snapshot

Revenues TTM
$15,534,700,000
NetIncome TTM
$4,328,700,000
OpCashFlow TTM
—
Assets (Latest)
$41,730,600,000
Forward EPS
$66.94

Max Pain — expiry 2026-12-18

max pain strike: $735.00 · spot: $945.53 · call oi: 439 · put oi: 691
Expected Move to 2026-12-18: ±$80.60 (8.52%) — implied range $864.93 – $1026.13 · ATM straddle on $945.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GSK GSK plc $98.62B $49.24 —
SNY Sanofi $113.89B $47.53 —
BMY BRISTOL MYERS SQUIBB CO $125.40B $61.35 —
VRTX VERTEX PHARMACEUTICALS INC / MA $135.44B $534.20 —
NVO NOVO NORDISK A S $136.10B $40.70 —

News headlines (Yahoo Finance, 1h cache)

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
2026-11-18 23:03 · Yahoo
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
2026-11-18 18:10 · Yahoo
Should You Pick Vertex Stock Over Its Biotech Rivals?
2026-11-18 17:13 · Yahoo
Does Flexible Libtayo Dosing Change The Bull Case For Regeneron Pharmaceuticals Stock?
2026-11-18 07:08 · Yahoo
Regeneron Pharmaceuticals (REGN), Why Is The Market Taking A Closer Look?
2026-11-18 06:15 · Yahoo
Regeneron (REGN) Stock Trades Below Fair Value As POTS Trial Progresses
2026-11-18 05:10 · Yahoo
CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
2026-11-17 21:15 · Yahoo
Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval
2026-11-17 18:13 · Yahoo
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
2026-11-17 15:00 · Yahoo
Can Regeneron Stock Hit $1,400?
2026-11-17 14:13 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.